Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

NewAmsterdam Pharma Co N.V (NAMS) Shares Outstanding: 2022-2025

Historic Shares Outstanding for NewAmsterdam Pharma Co N.V (NAMS) over the last 3 years, with Sep 2025 value amounting to $113.2 million.

  • NewAmsterdam Pharma Co N.V's Shares Outstanding rose 22.79% to $113.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $113.2 million, marking a year-over-year increase of 22.79%. This contributed to the annual value of $108.1 million for FY2024, which is 31.04% up from last year.
  • Latest data reveals that NewAmsterdam Pharma Co N.V reported Shares Outstanding of $113.2 million as of Q3 2025, which was up 0.59% from $112.5 million recorded in Q2 2025.
  • NewAmsterdam Pharma Co N.V's 5-year Shares Outstanding high stood at $113.2 million for Q3 2025, and its period low was $81.6 million during Q4 2022.
  • Moreover, its 3-year median value for Shares Outstanding was $90.0 million (2024), whereas its average is $95.2 million.
  • Data for NewAmsterdam Pharma Co N.V's Shares Outstanding shows a peak YoY soared of 31.04% (in 2024) over the last 5 years.
  • Quarterly analysis of 4 years shows NewAmsterdam Pharma Co N.V's Shares Outstanding stood at $81.6 million in 2022, then rose by 1.12% to $82.5 million in 2023, then skyrocketed by 31.04% to $108.1 million in 2024, then increased by 22.79% to $113.2 million in 2025.
  • Its Shares Outstanding stands at $113.2 million for Q3 2025, versus $112.5 million for Q2 2025 and $112.2 million for Q1 2025.